These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 16531262)

  • 21. Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy.
    Yanada M; Sugiura I; Takeuchi J; Akiyama H; Maruta A; Ueda Y; Usui N; Yagasaki F; Yujiri T; Takeuchi M; Nishii K; Kimura Y; Miyawaki S; Narimatsu H; Miyazaki Y; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R;
    Br J Haematol; 2008 Nov; 143(4):503-10. PubMed ID: 18986386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Late appearance of Philadelphia chromosome with the p190 BCR/ABL chimeric transcript in acute myelogenous leukemia progressing from myelodysplastic syndrome.
    Kakihana K; Mizuchi D; Yamaguchi M; Sakashita C; Fukuda T; Yamamoto K; Miki T; Murakami N; Miura O
    Rinsho Ketsueki; 2003 Apr; 44(4):242-8. PubMed ID: 12784657
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transient pancytopenia preceding acute lymphoblastic leukemia with positive Philadelphia chromosome.
    Li Q; Chen Z; You Y; Zou P
    Leuk Res; 2008 Aug; 32(8):1317-20. PubMed ID: 18291524
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen.
    Storring JM; Minden MD; Kao S; Gupta V; Schuh AC; Schimmer AD; Yee KW; Kamel-Reid S; Chang H; Lipton JH; Messner HA; Xu W; Brandwein JM
    Br J Haematol; 2009 Jun; 146(1):76-85. PubMed ID: 19438471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monitoring molecular response by BCR-ABL, JH and WT-1 in Ph+ all treated with imatinib containing regimen: preliminary report of two cases.
    Miglino M; Varaldo R; Colombo N; Grasso R; Clavio M; Garuti A; Aquino S; Albarello A; Sessarego M; Gobbi M
    J Exp Clin Cancer Res; 2006 Sep; 25(3):321-4. PubMed ID: 17167971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 9q34 rearrangements in BCR/ABL fusion-negative acute lymphoblastic leukemia.
    Dave BJ; Wiggins M; Higgins CM; Pickering DL; Perry D; Aoun P; Abromowich M; DeVetten M; Sanger WG
    Cancer Genet Cytogenet; 2005 Oct; 162(1):30-7. PubMed ID: 16157197
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A multicenter total therapy strategy for
    Chiaretti S; Ansuinelli M; Vitale A; Elia L; Matarazzo M; Piciocchi A; Fazi P; Di Raimondo F; Santoro L; Fabbiano F; Califano C; Martinelli G; Ronco F; Ferrara F; Cascavilla N; Bigazzi C; Tedeschi A; Sica S; Di Renzo N; Melpignano A; Beltrami G; Vignetti M; Foa R
    Haematologica; 2021 Jul; 106(7):1828-1838. PubMed ID: 33538150
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increasing the BCR-ABL expression levels and/or the occurrence of ABL point mutations does not always predict resistance to Imatinib Mesylate in BCR-ABL positive acute lymphoblastic leukemia.
    Grammatico S; Elia L; Peluso AL; Pedace L; Matarazzo M; Vitale A; Rago A; Pane F; Foà R; Cimino G
    Leuk Res; 2009 Jul; 33(7):e73-4. PubMed ID: 19108887
    [No Abstract]   [Full Text] [Related]  

  • 29. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros.
    Mullighan CG; Miller CB; Radtke I; Phillips LA; Dalton J; Ma J; White D; Hughes TP; Le Beau MM; Pui CH; Relling MV; Shurtleff SA; Downing JR
    Nature; 2008 May; 453(7191):110-4. PubMed ID: 18408710
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Prognostic factors for childhood acute non-mature B-lymphoblastic leukemia].
    Jiang H; Gu LJ; Xue HL; Tang JY; Chen J; Pan C; Chen J; Xu C; Dong L; Zhou M
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):290-4. PubMed ID: 18554450
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proportion of long-term event-free survivors and lifetime of adult patients not cured after a standard acute lymphoblastic leukemia therapeutic program: adult acute lymphoblastic leukemia-94 trial.
    Le QH; Thomas X; Ecochard R; Iwaz J; Lhéritier V; Michallet M; Fiere D
    Cancer; 2007 May; 109(10):2058-67. PubMed ID: 17407135
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Philadelphia chromosome-positive acute lymphoblastic leukemia showing normal karyotype at presentation].
    Maki K; Nakamura F; Gunji H; Arai Y; Mitani K
    Rinsho Ketsueki; 2003 Nov; 44(11):1110-2. PubMed ID: 14689877
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of P190 and P210 BCR/ABL1 in normal human CD34(+) cells induces similar gene expression profiles and results in a STAT5-dependent expansion of the erythroid lineage.
    Järås M; Johnels P; Agerstam H; Lassen C; Rissler M; Edén P; Cammenga J; Olofsson T; Bjerrum OW; Richter J; Fan X; Fioretos T
    Exp Hematol; 2009 Mar; 37(3):367-75. PubMed ID: 19135771
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bcr/Abl P190 interaction with Spa-1, a GTPase activating protein for the small GTPase Rap1.
    Yi SJ; Lee HT; Groffen J; Heisterkamp N
    Int J Mol Med; 2008 Oct; 22(4):453-8. PubMed ID: 18813851
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcome of adult T-lymphoblastic lymphoma after acute lymphoblastic leukemia-type treatment: a GOELAMS trial.
    Hunault M; Truchan-Graczyk M; Caillot D; Harousseau JL; Bologna S; Himberlin C; Guyotat D; Berthou C; Casassus P; Baranger L; Béné MC; Ifrah N; Gyan E;
    Haematologica; 2007 Dec; 92(12):1623-30. PubMed ID: 18055985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study.
    Huguet F; Leguay T; Raffoux E; Thomas X; Beldjord K; Delabesse E; Chevallier P; Buzyn A; Delannoy A; Chalandon Y; Vernant JP; Lafage-Pochitaloff M; Chassevent A; Lhéritier V; Macintyre E; Béné MC; Ifrah N; Dombret H
    J Clin Oncol; 2009 Feb; 27(6):911-8. PubMed ID: 19124805
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response.
    Press RD; Galderisi C; Yang R; Rempfer C; Willis SG; Mauro MJ; Druker BJ; Deininger MW
    Clin Cancer Res; 2007 Oct; 13(20):6136-43. PubMed ID: 17947479
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is p190 bcr-abl rearrangement necessary for acute transformation in some p210 CML of childhood?
    Scrideli CA; de Oliveira FM; Brassesco MS; de Paula Queiroz R; Bernardes JE; Valera ET; Tone LG
    Leuk Res; 2009 Mar; 33(3):495-9. PubMed ID: 18495245
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Major molecular response to imatinib in a patient with acute mixed lineage leukemia expressing a novel BCR/ABL transcript].
    Liu HX; Cao XY; Tong CR; Wu T; Wang T; Fan QZ; Wu P; Zhang X; Cai P; Zhu P
    Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(4):220-3. PubMed ID: 19552835
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Methodologic and biological variability of quantitative real-time polymerase chain reaction analysis of Bcr-Abl expression in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Scheuring UJ; Pfeifer H; Wassmann B; Brück P; Hoelzer D; Ottmann OG
    Haematologica; 2003 Sep; 88(9):1074-6. PubMed ID: 12969819
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.